Changing etiologies and outcome of liver failure in Southwest China by Gui-Juan Xie et al.
RESEARCH Open Access
Changing etiologies and outcome of liver
failure in Southwest China
Gui-Juan Xie*, Hui-Yan Zhang, Qing Chen, Hui-Min Liu, Jian-Ping You, Sha Yang, Qing Mao and Xu-Qing Zhang*
Abstract
Background: The prognosis of liver failure depends greatly on the underlying cause, and there were few data
about the prognosis, etiologies or trigger factors of liver failure in China based on long-term and large samples
cohorts.
Methods: We screened out 3171 liver failure cases from 25467 patients hospitalized in our department between
2000 and 2012 according to Chinese criteria, and determined their etiologies and prognosis.
Results: 97.3 % cases were associated with at least one of 25 identified factors. The 3 leading etiologies were HBV
(91.6 %), alcohol (18.1 %) and antiviral therapy (AVT) related hepatitis B flares (6.7 %). Acute-on-chronic liver failure
(ACLF) accounted for 92.1 % of all cases. 96.5 % ACLF cases were associated with HBV, in which the percentage of
AVT related flares increased from 0 % in 2000 up to 11.5 % in 2012, and hepatitis virus superinfection declined from
peak 19.3 % in 2002 down to 2.5 % in 2012. Three-month spontaneous survival (SS) rate of 3171 cases was 31.4 %,
but improved from 17.4 % in 2000 up to 40.4 % in 2012. SS was significantly different among various etiological groups
(P = 0.000). In HBV related liver failure aged 25 to 54 years, males accounted for 87.6 %, and had a progressively
decreased SS with increasing age. From 25 to 54 years, SS was lower in male than in female HBV related liver failure,
and having significant difference in cases of ages 40 to 44 years (27.6 % versus 50.9 %, P = 0.001).
Conclusion: Etiologies of liver failure were numerous and varied in southwest China. HBV was the most leading cause
of liver failure, especially in ACLF. AVT related flares had become the third leading cause of ACLF. The prognosis of liver
failure remained poor, but had markedly improved in recently 3 years. Middle-aged male HBsAg carriers had an
extremely higher risk for liver failure and worse prognosis compared to female.
1. Etiologies of liver failure were numerous and varied in southwest China. HBV infection is the main cause of liver
failure in southwest China, especially the major cause of ACLF. Antiviral related liver failure, especially the NUCs
withdrawal induced ACLF were extremely increased, which has replaced the superinfection as the third important
cause of HBV-ACLF.
2. The prognosis of liver failure is still poor, but the spontaneous survival rate showed a trend of steady rise in recent
years. The prognosis of patients with liver failure caused by different causes also exists certain difference, the more
damage factors bulls the worse prognosis.
3. The prognosis of the HBV and HCV reactivation induced by the steroids was poor.Interferon treatment of CHB in
ACLF although rare, but should be taken into consideration seriously.
4. Patients with liver failure caused by different etiologies showed larger differences of gender and age distribution.
Gender and age are the important factors with the occurrence and prognosis of HBV-ACLF.
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Background
Liver failure is a serious acute or chronic liver insuffi-
ciency induced by a variety of causes. However, there are
high diversity on the definition, classification and criteria
of liver failure in different countries [1]. In China, liver
failure is classified into acute liver failure (ALF), sub-
acute liver failure (SALF), acute-on-chronic liver failure
(ACLF) and chronic liver failure [2]. ALF or SALF is a
clinical syndrome characterized by acute liver decom-
pensation developed in the absence of pre-existing liver
disease [3]. ACLF is another clinical type of acute liver
decompensation resulting from a precipitating event
(acute insult) in patients with previously compensated
liver disease [4]. Acute liver decompensation may be re-
versible if the trigger factor is treated, but associated
with high short-term mortality in ALF, SALF and ACLF.
The main causal agents of liver failure show wide
geographical variation, and depend on the prevalent
hepatotropic virus infections and patterns of drug use.
Otherwise, the prognosis of liver failure depends greatly
on the underlying cause. Therefore, it is important to
perform a survey on the changing etiologies and trigger
factors of liver failure in China.
Numerous reports on the etiology of ALF and SALF
have been published in different countries. In USA, acet-
aminophen toxicity was the most common cause of ALF
[5]. Zhao reported that drug toxicity, indeterminate and
viral hepatitis were the main causes of ALF in China [6].
However, there are few epidemiological and etiological
studies regarding ACLF. China is a region of high preva-
lence of hepatitis B virus (HBV) infection. HBV associ-
ated ACLF is the most common clinical type of liver
failure in China [2]. The acute events that trigger the on-
set of liver failure in HBV carriers show wide geograph-
ical variation and vary in different periods [4]. Some
previous studies based on small samples cohorts showed
that hepatitis E virus (HEV) infection is a leading trigger
factor of ACLF in Bangladesh, India and southeast China
[7–9]. However, there were few data about the progno-
sis, etiologies or trigger factors of liver failure in China
based on long-term and large samples cohorts. Other-
wise, it is also not consistent about the association of
prognosis with etiologies, sex and age in previously
published data. In this study, we performed an extensive
investigation on 3171 liver failure patients admitted in
our department from 2000 to 2012, in order to clarify
the prognosis and epidemiological characteristics of liver
failure in China, which included transplant-free or spon-




Figure 1 shows the enrollment of patients in this
retrospective study. Firstly, we made a search in
computerized diagnoses hospital registry for all pa-
tients admitted to department of infectious diseases,
Southwest hospital of Chongqing, China from January
Fig. 1 Enrollment of patients in this study. Abbreviation: ALF, acute liver failure; SALF, sub-acute liver failure; ACLF, acute-on-chronic liver failure;
PTA, prothrombin activity; TBil, total bilirubin
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2000 to December 2012. A total of 25467 hospitalized
patients were indexed during the 13 years period.
Secondly, we screened out 4903 candidate cases for
assumed liver failure according to the diagnostic re-
cords obtained from computerized diagnoses hospital
registry, which included 5 cases of fulminant hepatic
failure, 71 cases of liver failure, 52 cases of ALF, 48
cases of SALF, 62 cases of ACLF, 71 cases of fulminant
viral hepatitis, 56 cases of subfulminant viral hepatitis,
4135 cases of chronic severe hepatitis B, 7 cases of
chronic severe hepatitis C, 6 cases of severe acute
hepatitis B, 8 cases of severe alcoholic hepatitis, 6
cases of severe drug hepatitis, 325 cases of severe
chronic hepatitis B, 48 cases of Wilson’s disease and
13 cases of acute fatty liver of pregnancy (AFLP).
Thirdly, each of 4903 cases with assumed liver failure
was again determined to be whether or not fulfilled
the diagnostic criteria of ALF, SALF and ACLF in
China according to the following clinical data obtained
from the electronic medical records, which included
the levels of prothrombin activity (PTA) and serum
total bilirubin (T-Bil), the length of illness, a history of
underlying chronic liver disease, the grade of hepatic
encephalopathy (HE) and the time from onset of ill-
ness to development of HE. Inclusion criteria for ALF
included: ① serum T-Bil≧10 mg/dL or an increased T-
Bil/d ≧ 1 mg/dL; ② PTA ≤40 %; ③ the occurrence of
at least gradeII HE within 2 weeks of illness onset; ④
without pre-existing liver disease. Inclusion criteria
for SALF included: ① serum T-Bil≧10 mg/dL; ②PTA
≤40 %; ③the length of illness <26 weeks with or with-
out HE; ④ without pre-existing liver disease. Inclusion
criteria for ACLF was an onset of acute liver decom-
pensation within 12 weeks in a patient with previously
diagnosed or undiagnosed chronic liver disease, and
included the following evidences: ① serum T-
Bil≧10 mg/dL; ②PTA ≤40 %. Finally, 3171 patients
were enrolled in this study based on the above inclu-
sion criteria, which included 75 cases of ALF, 174
cases of SALF and 2922 cases of ACLF. Among 3171
patients with liver failure, 3118 (98.33 %) cases were
from Southwest areas of China, which included
Chongqing (60.99 %), Sichuan (32.17 %), Guizhou
(4.73 %), Yunnan province (0.28 %), Tibet (0.09 %) and
Guangxi (0.06 %). Another 53 cases (1.67 %) were from
other areas of China, which included Liaoning, Jilin,
Anhui, Jiangsu, Jiangxi, Zhejiang, Fujian, Guangdong,
Hainan, Hubei, Hunan, Shanxi, Henan, Shandong prov-
ince and Xinjiang. After informed consent was obtained
from the next of kin, detailed prospective clinical and
laboratory data were collected in an anonymous fashion
on admission to our hospital. The protocol was ap-
proved by the Ethics Committee of Southwest Hospital,
Chongqing, China.
Defining the etiologies and trigger factors of liver failure
Viral infection was defined based on serum markers for
hepatitis A-E, human immunodeficiency virus (HIV),
herpes simplex virus (HSV), Epstein-Barr virus (EBV)
and cytomegalovirus (CMV). All 3171 patients were
tested for serum anti-HAV IgM, HBsAg and HBV DNA,
anti-HCV, HDAg and anti-HDV, anti-HEV IgM, and
anti-HIV. Only patients who did not suffer from hepa-
titis A-E were tested for IgM antibody of HSV, EBV and
CMV. Autoimmune hepatitis (AIH) was diagnosed
based on descriptive clinical criteria reported by the
International Autoimmune Hepatitis Group [10]. Alco-
holic liver disease (ALD) was considered for patients
who had taken alcohol at least 3 years, and a regular
average consumption of ethanol >40 g/day for women
and >60 g/day for men in this article [11]. Drug induced
liver injury (DILI) was considered for patients who had
taken any hepatotoxic drugs or Chinese herbs within
6 months before this illness onset. Wilson’s disease was
diagnosed according to the criteria recommended by
European Association for the Study of the Liver. The
clinical diagnosis for other diseases was obtained from
the electronic medical records, included hyperthyroid-
ism, schistosomiasis japonica, AFLP, acute pancreatitis,
septic cholangitis and tumors. The etiology of liver fail-
ure was considered to be indeterminate if no diagnostic
clues were obtained from the patient’s history, serologic
markers for HAV, HBV, HCV, HEV, CMV, EBV, HSV,
HIV, anti-smooth-muscle or antinuclear antibodies and
ceruloplasmin (or other signs of Wilsons disease). Trig-
ger factors of liver failure included the following events:
① nucleos(t)ide analogues (NUCs) withdrawal, which
was defined as HBV reactivation and abnormal liver
function test within 52 weeks of withdrawal from NUCs
therapy among patients who received at least 12 weeks
NUC therapy; ② resistance to NUCs; ③ steroids use in-
duced HBV reactivation; ④ interferon (IFN) therapy in-
duced severe acute exacerbation (SAE) of chronic
hepatitis B (CHB); ⑤ other factors, such as surgery and
pregnancy. Bacterial infection was not defined as a trig-
ger factor in HBV associated liver failure because that
this infection was not identified to be existed prior to
onset of liver failure or secondary to liver failure. We de-
fined ACLF induced by NUCs withdrawal, resistance to
NUCs and IFN therapy as antiviral therapy related ACLF
(AVT-ACLF).
Statistical analysis
For processing the data, Microsoft Office Excel 2010
(Microsoft, Redmond, WA) and IBM SPSS Statistics
(IBM, Armonk, NY) were used. The data are shown in
medians and interquartile ranges. Continuous variables
were summarized as mean ± standard deviation (SD),
median (range), or frequency (in percent). Categorical
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variables were compared with the chi-square test and
Fisher’s exact test. A p value of <0.05 was considered sta-
tistically significant.
Results
Distribution and trend of etiologies for liver failure
In this study, 3171 patients were enrolled to be analyzed
for etiologies of liver failure, in which 3086 (97.3 %)
cases were identified to be associated with at least one of
several causal agents for hepatic injury, and 85 (2.7 %)
cases were indeterminate etiology. A total of 25 precipi-
tating factors were identified in 3171 patients, in which
the 5 leading causes were HBV (91.6 %), alcohol
(18.1 %), antiviral therapy (AVT) related hepatitis flares
(6.7 %), drugs (5.4 %) and HEV (3.2 %), shown in Table 1.
Among 171 patient with DILI, 107 (62.6 %) had received
antituberculosis drugs, 41 (24.0 %) had received Chinese
herbs and 23 (13.5 %) had received other drugs which
included nonsteroidal anti-inflammatories drugs (3.5 %),
acetaminophen (2.3 %), antibiotics (1.8 %), leflunomide
(1.8 %), statins (1.2 %), methimazole (1.2 %), anticancer
drug (0.6 %), cyclosporine A (0.6 %) and chlorpromazine
(0.6 %). Among 164 ACLF induced by withdrawal of
NUCs, the percentage of cases after the withdrawal from
lamivudine was 53.7 %, adefovir 26.8 %, entecavir 9.8 %,
telbivudine 4.9 %, lamivudine and adefovir 4.9 %. Among
37 patients with HBV resistance to NUCs, the percent-
age of cases with resistance to lamivudine was 67.6 %,
adefovir 16.2 %, telbivudine 8.1 %, adefovir and lamivu-
dine 5.4 %, adefovir and entecavir 2.7 %.
The distribution of etiologies showed wide variation in
different clinical type of liver failure. The 3 leading
causes were single HBV infection (46.7 %), indetermin-
ate (20.0 %) and DILI (17.3 %) for ALF (Fig. 2), but being
indeterminate (29.3 %), single HBV infection (25.3 %)
and DILI (25.3 %) for SALF (Fig. 3). Among 2922 pa-
tients with ACLF, 2821 (96.5 %) cases were associated
with HBV infection, but only 101 (3.5 %) cases being
non-HBV associated ACLF. Among 2821 patients with
HBV associated ACLF, 1057 (37.5 %) cases had more
than one precipitating factor, in which the 3 leading trig-
ger factors were alcohol, superinfection and NUCs with-
drawal (Fig. 4). The percentages of patients with at least
two precipitating factors were significantly higher in
ACLF (36.7 %, 1071/2922) than those in ALF (6.7 %, 5/
75) and SALF (1.7 %, 3/174), P = 0.000.
The distribution of etiologies for liver failure also
showed wide variation during the 13 years periods.
Figures 5–6 showed the trends of common etiologies.
The etiologies with a declined trend included HAV,
HCV, HDV, HEV infection, while those of having an
increased trend included ALD, NUCs withdrawal and re-
sistance to NUCs. For ACLF, the 3 leading etiologies
were spontaneous SAE of CHB (58.2 %, 286/491), hepa-
totropic viruses superinfection (17.1 %, 82/491) and
HBV plus alcohol (14.3 %, 70/491) between 2001 and
2003, but were spontaneous SAE of CHB (58.9 %, 989/
Table 1 The etiologies of 3171 patients with liver failure
Etiologies Frequency (%) Etiologies Frequency (%)
HBV 2906 (91.64 %) Hyperthyroidism 21 (0.66 %)
HEV 102 (3.22 %) Tumor 21 (0.66 %)
HDV 74 (2.33 %) AIH 19 (0.60 %)
HAV 27 (0.85 %) Pregnancy 16 (0.50 %)
HCV 23 (0.73 %) Acute pancreatitis 10 (0.32 %)
HIV 12 (0.38 %) AFLP 8 (0.25 %)
CMVa 3 Wilson’s disease 6 (0.19 %)
EBVa 2 Schistosomiasis japonica 2 (0.06 %)
HSVa 2 Septic cholangitis 2 (0.06 %)
Alcohol 573 (18.07 %) Indeterminate 85 (2.68 %)
Medicinal factor 452 (14.25 %)
Drugsb 171 (5.39 %)
Withdrawal of NUCs 164 (5.17 %)
Steroids use 63 (1.99 %)
Resistance to NUCs 37 (1.17 %)
IFN therapy 12 (0.38 %)
Surgery 7 (0.22 %)
aOnly patients who were negative for HAV, HBV, HCV, HDV and HEV were tested for serum IgM antibody of cytomegalovirus (CMV), Epstein-Barr virus (EBV) and
herpes simplex virus (HSV). bincluded 2 cases of steroids use
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1678), HBV plus alcohol (20.3 %, 341/1678) and medi-
cinal factors (15.7 %, 264/1678) including 170 (10.1 %)
cases of AVT-ACLF between 2007 and 2012. Cases in-
duced by hepatotropic viruses superinfection and HBV
plus drugs only accounted for 2.4 % and 3.0 % of all
1678 ACLF patients between 2007 and 2012.
Demographical characteristics of patients with liver
failure
Demographical characteristics of liver failure in different
clinical types and etiologies are depicted in Table 2. The
ratio of male to female was 5.6:1 in ACLF, which was
significantly higher than that in ALF (1.3:1) and SALF
(0.9:1), P = 0.000. Patients with ACLF tended to be older
than those with SALF and ALF (P = 0.000). There were
no significant difference with age (P = 0.122) and sex
(P = 0.269) between SALF and ALF. The ratio of male
to female was 5.9:1 in HBV associated liver failure,
which was significantly higher than that (0.9:1) in
non-HBV associated liver failure (P = 0.000), but hav-
ing no significant difference with age between two
groups (P = 0.258). Patients with liver failure induced
by Chinese herbs tended to be older (P = 0.001) and
more likely to be female (P = 0.000) than those with
liver failure induced by antituberculosis drugs. Patients with
indeterminate liver failure tended to be younger (P = 0.015)
and more likely to be female (P = 0.000) than those of HBV
associated liver failure. In HBV associated liver failure, male
Fig. 2 Distribution of etiologies of liver failure in ALF Southwest China
Fig. 3 Distribution of etiologies of liver failure in SALF Southwest China
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patients (41.5 ± 11.3 years) tended to be younger than fe-
male (45.3 ± 13.0 years) cases (P = 0.000). 81.1 % patients
with HBV related liver failure were aged 25–54 years in
male, while only 67.2 % cases were aged 25–54 years in fe-
male, the ratio of male to female reached 7.1:1 (Table 3).
Prognosis of liver failure
In this study, only 66 (2.1 %) patients received a liver
transplant, and 45 (68.2 %) survived within 1 year of
post-transplant. During the 13 years, the average 3-
month SS rates of liver failure were 31.4 % (996 of
3171), but showed a gradually increased trend (Table 4).
SS rates were 41.1 % (401/976) in 3 years between 2010
and 2012, which were significantly higher than 32.4 %
(344/1063) in 4 years between 2006 and 2009 (P =
0.000), and 22.2 % (251/1132) in 6 years between 2000
and 2005 (P = 0.000).
SS rate of ALF was 17.3 % (13/75), which was signifi-
cantly lower than 29.3 % (51/174) of SALF and 31.9 %
(932/2922) of ACLF (P = 0.047, 0.007). In SALF and
ACLF group, SS rates of patients with HE were 6.3 % (6/
95) and 8.0 % (100/1245), which were significantly lower
than 57.0 % (45/79) and 49.6 % (832/1677) of patients
without HE (P = 0.000). In fact, SS rate was significantly
higher in ALF (17.3 %) than in SALF (6.3 %) and ACLF
(8.0 %) with HE (P = 0.028, 0.010).
Fig. 4 Distribution of etiologies of HBV related liver failure in ACLF Southwest China
Fig. 5 Changing common etiologies or trigger factors liver failure in Southwest China from 2000 to 2012
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Fig. 6 Changing common etiologies or trigger factors liver failure in Southwest China from 2000 to 2012. ALD, alcoholic liver disease; AVT-ACLF,
antiviral therapy related ACLF; NUCs, nucleos (t)ide analogues; CHB, chronic hepatitis B; S-SAE, spontaneous SAE of CHB
Table 2 Demographical characteristics of patients with liver failure
Sex (%) Age
Male Female P value (years) P value
All cases (n = 3171) 82.18 % 17.82 % 41.9 ± 12.4 (0.5–83)
Clinical types
ALF (n = 75)a 56.00 % 44.00 % 0.000 33.7 ± 17.5 (0.5–76) 0.000
SALF (n = 174)a 47.70 % 52.30 % 0.000 37.4 ± 17.4 (3–79) 0.000
ACLF (n = 2922) 84.90 % 15.10 % 42.4 ± 11.7 (8–83)
HBV (n = 2906) 85.40 % 14.60 % 42.0 ± 11.7 (8–83)
non-HBV (n = 265)b 47.20 % 52.80 % 0.000 40.7 ± 18.4 (0.5–79) 0.258
ALD (n = 573) 98.40 % 1.60 % 0.000 46.0 ± 10.3 (21–77) 0.000
DILI (n = 171) 69.60 % 30.40 % 0.000 41.7 ± 14.7 (4–75) 0.658
Antituberculosis (n = 107) 85.00 % 15.00 % 39.1 ± 12.2 (16–72)
Chinese herbs (n = 41)& 36.60 % 63.40 % 0.000 48.6 ± 14.9 (11–72) 0.001
HAV (n = 27) 85.20 % 14.80 % 0.570 36.4 ± 15.2 (3–75) 0.033
HEV (n = 102) 89.20 % 10.80 % 0.167 42.2 ± 13.9 (17–81) 0.419
HDV (n = 74) 86.50 % 13.50 % 0.478 43.8 ± 11.7 (14–68) 0.084
HCV (n = 23) 87.00 % 13.00 % 0.563 38.4 ± 10.4 (24–64) 0.116
Withdrawal (n = 164) 84.30 % 15.70 % 0.506 42.5 ± 10.4 (20–71) 0.363
Resistance (n = 37) 83.80 % 16.20 % 0.461 42.4 ± 9.8 (13–63) 0.400
Steroids use (n = 63) 74.60 % 25.40 % 0.018 46.4 ± 12.5 (22–69) 0.005
Indeterminate (n = 85)b 37.60 % 62.40 % 0.000 38.8 ± 20.0 (0.5–79) 0.015
The results are shown as median and range
ALF acute liver failure, SALF sub-acute liver failure, ACLF acute-on-chronic liver failure, ALD Alcoholic liver disease, DILI Drug induced liver injury
aALF, SALF VS ACLF;b Non-HBV VS HBV; & Chinese herbs VS Antituberculosis
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Figure 7 showed SS rates of patients according to the
etiology amongst the major etiological groups of liver
failure. There were significant difference with SS rates
among different etiological groups (P = 0.000). In HBV
associated ACLF, SS rate of patients induced by alcohol,
drugs, NUCs withdrawal and resistance to NUCs was
29.1 % (223/766), which was significantly lower than
those of spontaneous SAE (34.1 %, 601/1764) and
hepatotropic viruses superinfection (38.5 %, 55/143),
P = 0.014, 0.030. There were no significant difference
with SS rates between spontaneous SAE and hepato-
tropic viruses superinfection groups (P = 0.314).
Spontaneous survivors (36.9 ± 17.3 years) tended to be
younger than patients who were not spontaneous survi-
vors whether in non-HBV (36.9 ± 17.3 versus 42.2 ± 18.7,
P = 0.035) or HBV associated liver failure (38.6 ± 11.0
versus 43.6 ± 11.6, P = 0.000). There was no significant
difference with SS rate between male (28.8 %, 36/125)
and female (27.9 %, 39/140) patients (P = 0.865) in non-
HBV associated liver failure. In HBV associated liver fail-
ure, SS rate was higher in female (35.4 %, 150/424) than
31.1 % (771/2482) of male patients, but having no statis-
tically significant difference (P = 0.08). Table 3 showed
the relationship of outcome with sex and age of patients
in HBV associated liver failure. For male patients, there
were significant difference with SS rates among different
age groups (P = 0.000), which SS rate was the highest in
those aged 20–24 years (63.1 %, 53/84), then decreased
progressively with increasing age. For male, SS rate was
significantly higher in patients aged 30–34 years (41.8 %)
than 30.3 % of aged 35–39 years group (P = 0.001). For
female, no significant difference was observed with SS
rates among different age groups below 55 years (P =
0.564), and also among different age groups over 55 years
(P = 0.322), but SS rate was significantly higher in pa-
tients aged <55 years group (42.5 %, 131/308) than
16.4 % (19/116) of aged ≥55 years group (P = 0.000).
SS rates were higher in male than in female patients
aged <25 years [59.8 % (73/122) versus 43.5 % (10/
23)] and ≥55 years [18.7 % (65/347) versus 16.4 %
(19/116)] group, though having no statistically signifi-
cant difference (P = 0.154, 0.569). However, SS rates
Table 3 The distribution of sex, age and etiologies, and their association with outcome in HBV related liver failure
N of cases Distribution M/F SS rates ALD Medicinal factors Superinfection
Age Male Female Male Female ratio Male Female P value Male Male Female Male Female
<15 8 2 0.3 % 0.5 % 4.0 50.0 % 50.0 % 0.326 0.0 % 12.5 % 0.0 % 0.0 % 50.0 %
15–19 30 6 1.2 % 1.4 % 5.0 53.3 % 33.3 % 0.584 0.0 % 0.0 % 0.0 % 6.7 % 0.0 %
20–24 84 15 3.4 % 3.5 % 5.6 63.1 % 46.7 % 0.077 4.8 % 13.1 % 26.7 % 6.0 % 6.7 %
25–29 188 28 7.6 % 6.6 % 6.7 42.0 % 46.4 % 0.686 7.4 % 11.2 % 3.6 % 8.5 % 0.0 %
30–34 359 39 14.5 % 9.2 % 9.2 41.8 % 51.3 % 0.307 12.0 % 11.1 % 7.7 % 6.7 % 15.4 %
35–39 525 66 21.2 % 15.6 % 8.0 30.3 % 39.4 % 0.159 17.7 % 11.0 % 9.1 % 5.5 % 6.1 %
40–44 427 57 17.2 % 13.4 % 7.5 27.6 % 50.9 % 0.001 24.1 % 13.8 % 10.5 % 4.4 % 1.8 %
45–49 307 43 12.4 % 10.1 % 7.1 26.7 % 39.5 % 0.103 29.6 % 18.2 % 16.3 % 6.8 % 2.3 %
50–54 207 52 8.3 % 12.3 % 4.0 21.7 % 30.8 % 0.201 32.4 % 10.1 % 21.2 % 9.7 % 0.0 %
55–59 156 55 6.3 % 13.0 % 2.8 21.8 % 14.5 % 0.175 31.4 % 14.7 % 20.0 % 8.3 % 5.5 %
60–64 101 37 4.1 % 8.7 % 2.7 18.8 % 24.3 % 0.811 34.7 % 14.9 % 13.5 % 5.0 % 5.4 %
≧65 90 24 3.6 % 5.7 % 3.8 13.3 % 8.3 % 0.730 28.9 % 11.1 % 8.3 % 6.7 % 4.2 %
Total 2482 424 100.0 % 100.0 % 5.9 31.1 % 35.4 % 21.2 % 12.7 % 13.2 % 6.4 % 4.7 %
SS spontaneous survival, ALD Alcoholic liver disease
P value: SS in male versus in female
Table 4 Spontaneous survival (SS) rates of patients with liver failure
All patients Clinical types Etiologies
Years N SS ALF SALF ACLF non-HBV HBV
2000 155 17.4 % 0.0 % 0.0 % 19.0 % 0.0 % 19.0 %
2001 179 22.9 % 0.0 % 0.0 % 25.3 % 0.0 % 24.6 %
2002 190 22.1 % 0.0 % 22.2 % 22.7 % 8.3 % 23.0 %
2003 169 27.2 % 40.0 % 27.3 % 26.8 % 9.1 % 28.5 %
2004 206 25.7 % 33.3 % 0.0 % 26.2 % 20.0 % 26.2 %
2005 233 18.0 % 16.7 % 28.6 % 17.7 % 18.8 % 18.0 %
2006 219 33.3 % 0.0 % 45.5 % 34.0 % 35.3 % 33.2 %
2007 260 33.1 % 0.0 % 28.6 % 34.2 % 33.3 % 33.1 %
2008 278 31.7 % 0.0 % 41.2 % 31.6 % 30.0 % 31.8 %
2009 306 31.7 % 25.0 % 26.3 % 32.3 % 35.1 % 31.2 %
2010 347 42.9 % 40.0 % 42.1 % 43.1 % 47.4 % 42.4 %
2011 332 39.8 % 50.0 % 29.4 % 40.3 % 36.4 % 40.1 %
2012 297 40.4 % 0.0 % 47.1 % 40.3 % 26.9 % 41.7 %
Total 3171 31.4 % 17.3 % 29.3 % 31.9 % 28.3 % 31.7 %
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of female were all higher than those of male patients
in each group of ages 25 to 54 years old. During ages
of 40 to 44 years, SS rate was significantly higher in
female (50.9 %, 29/57) than 27.6 % (118/427) of male
patients, P = 0.001.
Discussion
The current study is the first systematic investigation on
the presumed etiologies or trigger factors and prognosis
of patients with liver failure in Southwest China. Al-
though all data were collected only in our hospital, we
considered that our results were able to reflect the real-
life characteristics of liver failure in Southwest China be-
cause that 98.3 % enrolled patients were not only from
Chongqing city, but also from other five provinces of
Southwest China. Our results showed that ACLF was
the predominant clinical type of liver failure in South-
west China accounting for 2922 out of 3171 cases
(92.1 %), being similar with other results reported in
other area of China [12]. Among 1343 hospitalized
patients with cirrhosis from Europe, the prevalence of
ACLF was 30.9 % [13]. However, there was no data
about the percentage of ACLF in liver failure from
developed countries.
The etiologies or trigger factors of liver failure are
numerous and varied, including primary hepatotropic
viruses, secondary hepatotropic viruses, drug, alcohol,
metabolic causes, AIH, pregnancy, and so on. In this
study, a total of 25 etiologies or trigger factors were
identified to be associated with the onset of liver failure,
in which the 5 leading causes were HBV, alcohol, drug,
withdrawal of NUCs and HEV. But, another 2.68 % pa-
tients remained indeterminate etiology after extensive
evaluation. However, the contribution of each etiology
was different in ALF, SALF and ACLF. The 3 leading
causes of ALF and SALF all included single HBV infec-
tion, indeterminate and drugs, but the first common
cause was single HBV infection in ALF accounting for
46.7 % cases, and indeterminate in SALF accounting for
29.3 % cases. Our result was similar with the report from
Japan, but showed a significant difference compared
with other reports from western developed countries
and other areas of China [14]. According to our investi-
gation, HBV infection absolutely predominated in the
etiologies of ACLF accounting for 96.5 % cases in China,
which could be significantly different in western devel-
oped countries, because that the most common etiology
of chronic liver disease was HBV infection in China [2],
but was alcoholism in western developed countries [1].
The major etiologic agents responsible for precipitating
ACLF are quite distinct in the East and the West.
Alcohol and drugs constitute the majority of acute
insults in the West, whereas infectious etiologies
predominate in the East [9]. In Bangladesh, acute HEV
infection was a leading cause of ACLF accounting for
21.7 % (15/69) patients [7]. According to an investigation
from Southeast China during the 12 years between 1993
and 2004, an important factor responsible for
Fig. 7 The outcome according to etiology amongst the different etiological groups of liver failure
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precipitating HBV associated ACLF was the superinfec-
tion of hepatotropic viruses accounting for 37.9 % (107/
282) patients, which included HAV (1.4 %), HCV
(6.4 %), HDV (1.8 %) and HEV (28.4 %) [9]. The causes
were not clear in another 62.1 % patients. Of these pa-
tients, the most possible cause was considered to be
spontaneous SAE of CHB. Our results showed that the
first leading cause of HBV associated ACLF was also
spontaneous SAE of CHB accounting for 62.5 % cases,
and the second leading cause was alcohol (15.4 %), and
the third leading cause was withdrawal of NUCs (5.7 %),
and the fourth leading cause was hepatotropic viruses
superinfection (5.2 %) during the 13 years between 2000
and 2012. However, the second leading cause of ACLF
was hepatotropic viruses superinfection accounting for
17.1 % cases during the 3 years between 2001 and 2003,
which was similar with the report from Southeast China.
Our results showed that the precipitating factors were
the most complex in ACLF, which included 29 different
patterns derived from 25 causal agents compared with
15 patterns of SALF and 11 patterns of ALF. Otherwise,
36.7 % patients had at least two precipitating factors in
ACLF, but only 6.7 % in ALF and 1.7 % in SALF.
During the 13 year period between 2000 and 2012, the
prevalence of HAV, HCV, HDV and HEV infection was a
gradually declined trend among patients with liver
failure of Southwest China, which was all lower than
2.5 % after 2006. These results indicate that hepatotropic
viruses other than HBV have not been the common
etiology of liver failure in current Southwest China. The
explanations for this included that safe blood products,
hepatitis A and E vaccines were widely used in China.
Antiviral therapy with NUCs has been confirmed to be
effective in preventing the disease progression of chronic
hepatitis B, but hepatitis flares related to NUCs therapy
has become an urgent clinical problem that we have to
face. Several reports showed that 10–20 % of patients
experienced withdrawal flares of hepatitis B after cessa-
tion of NUCs therapy [15, 16]. Hepatitis flares due to
HBV resistance are also common during NUCs therapy
[17]. Several case reports have been published about
ACLF induced by acute hepatitis flares due to the with-
drawal or resistance of NUCs. However, there was no
data about the contribution of antiviral therapy (AVT)
related hepatitis flare in the development of ACLF. Our
results showed that the percentages of patients with
ACLF due to withdrawal and resistance of NUCs were
gradually increased from none of 142 cases in 2000 up
to 9.4 % and 2.2 % in 2012. During the 13 year period,
the total contributions to the etiologies of ACLF were
7.3 % by ART related hepatitis flare, 6.2 % by superinfec-
tion of hepatotropic viruses, and 3.2 % by HBV plus
drugs. Importantly, the percentages of patients with
ART-ACLF were markedly increased from 0 % in 2000
up to 11.5 % in 2012, while the percentages of ACLF as-
sociated superinfection were rapidly decreased from
peak 19.3 % in 2002 down to 2.5 % in 2012. During the
6 year period between 2007 and 2012, AVT related
hepatitis flares (10.1 %) have become the third leading
cause of ACLF in place of superinfection (2.6 %) and
HBV plus drugs (3.0 %). These finding firstly indicated
that AVT related hepatitis flares played an important
role in the development of HBV associated ACLF. So,
doctors should pay more attention to the management
of CHB patients who received antiviral therapy. Other-
wise, our data showed that 61 (2.1 %) cases of ACLF
were associated with the reactivation of HBV (59 cases)
or HCV (2 cases) induced by steroids use. China is a re-
gion of high prevalence of HBV infection, and the car-
rier rate of HBsAg in adults is more than 8 % [17].
Many cases with known or unknown chronic HBV/HCV
infection need to receive an immunosuppressive treat-
ment because of suffering from other diseases. However,
the reactivation of HBV or HCV is common following
immunosuppressive treatment and is associated with a
high mortality [18, 19]. Our results also showed that ste-
roids use induced ACLF cases had a particularly dismal
SS rate of 11.1 %. Therefore, doctors must highlight the
screening for HBV and HCV infection in all candidates
of immunosuppressive treatment, and an effective anti-
viral therapy should be taken for patients with HBV or
HCV infection before receiving an immunosuppressive
treatment.
In this study, our results showed that ACLF was more
common in elderly male population compared to ALF
and SALF. The explanations for this included that
96.5 % ACLF cases were associated with chronic HBV
infection in this study, and elderly male tended to take
alcohol in China. Compared to antituberculosis drugs
induced liver failure, Chinese herbs induced liver failure
tended to be elderly female population. The possible rea-
son is that elderly females are more likely to take Chin-
ese herbs for treating diseases in China. Especially
importantly, our results showed that the development of
liver failure was more frequent in male HBV carriers
than in female carriers. The ratio of male to female in
HBV related liver failure was 5.9:1, which was signifi-
cantly higher than 1.5:1 (male 8.6 % versus female 5.7 %)
of HBsAg in China [20]. This sexual dimorphism was
also observed in HBV related cirrhosis and primary he-
patocellular carcinoma [21]. Otherwise, male patients
tended to be younger than female cases in HBV associ-
ated liver failure. 81.1 % male patients were aged 25–55
years, but 67.2 % female patients were aged 25–55 years,
the ratio of male to female was 7.1:1. These findings in-
dicated that male HBsAg carriers were at higher risk for
liver failure compared to female carriers. The possible
reason may be due, at least in part, to lower production
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of estrogen and a reduced response to the action of es-
trogen [22]. Estrogen is a potent endogenous antioxidant
which attenuates induction of redox sensitive transcrip-
tion factors and hepatocyte apoptosis by inhibiting
generation of reactive oxygen species, Furthermore, es-
tradiol can prevents the autocrine loop of reactive
oxygen species (ROS) by suppressing NADH/NADPH
oxidase activity, and has a cytoprotective effect against
hepatocyte injury. [23].
Our results showed that the average 3-month SS rate
of liver failure was only 22.2 % in 6 years between 2000
and 2005, but up to 32.4 % in 4 years between 2006 and
2009, and reached to 41.1 % in 3 years between 2010
and 2012. These results indicated that our ability in
treating liver failure has significantly improved. The
trend toward increased SS in the last 30 years was con-
sidered to be primarily attributed to improved critical
care management in developed countries [24]. In China,
the improved SS may be associated with the early intro-
duction of antiviral therapy for hepatitis B, steroids use,
plasma exchange and hemodiafiltration. Of course, it
was also attributed to the effective prevention and
treatment of complications, and improved critical care
management.
According to the diagnostic criteria of ALF, SALF and
ACLF in China, our results showed that SS rate of ALF
cases was significantly lower than SALF and ACLF cases.
However, SS rate of ALF cases was significantly higher
than SALF and ACLF cases with HE. For SALF and
ACLF, SS rate was significantly higher in cases without
HE than in cases with HE. These findings suggested that
the onset of HE was an important indicator of worse
prognosis among patients with liver failure.
As all known, the prognosis of liver failure also de-
pends on their etiologies. Patients with acetaminophen
toxicity had the best outcome in developed countries
[25]. Our results also showed that the SS rate was also
related to the cause of liver failure, which the highest SS
rate was AFLP, and the lowest was patients infected by
HIV combined with HBV or HCV. Our results showed
that patients with HBV related ACLF induced by alco-
hol, drugs, NUCs withdrawal and HBV resistance to
NUCs had significantly lower SS rate compared with
ACLF cases induced by spontaneous SAE of CHB and
hepatotropic viruses superinfection, but did not show
that SS rate was lower in patients with hepatotropic
viruses superinfection than in spontaneous SAE of CHB
cases. These findings indicated that alcohol, drugs,
NUCs withdrawal and HBV resistance responsible for
precipitating liver failure had more severely harmful ef-
fects on chronic HBV carriers compared with hepatotro-
pic virus superinfection. So, it is especially important for
chronic HBV carriers to avoid intake of alcohol and
hepatotoxic drugs, and for CHB patients with NUCs
treatment to avoid hepatitis flares due to NUCs with-
drawal and HBV resistance.
Older age has been widely confirmed to be associated
with the severity of various liver diseases and a poor
prognosis of ALF in many studies. Regev and Schiff re-
ported 3–5-fold increases in deaths due to liver diseases
in those over 65 years of age versus those under 45 years
[26]. From India, Dhiman et al. reported that age greater
than 50 years was an independent predictor of outcome
in patients with viral ALF [27]. Our data showed that
spontaneous survivors tended to be younger than pa-
tients who died or received a liver transplant whether in
non-HBV or in HBV related liver failure. In male pa-
tients with HBV related liver failure aged ≥25 years, SS
rates decreased progressively with increasing age, and a
statistically significant difference was observed firstly be-
tween age 30 to 34 years and 35 to 39 years group. In fe-
male cases of HBV related liver failure, SS rates were
only observed to be significantly higher in age <55 years
group than in age ≥55 years group. These findings also
indicated that older age was associated with a poor
prognosis of liver failure, especially in male patients
with HBV related liver failure. The mortality of HBV
related liver failure increased markedly with increas-
ing age ≥35 years in males and ≥55 years in females.
As the incidence of HBV related diseases being un-
equal between males and females, this sexual dimorph-
ism was also observed in the outcome of HBV related
diseases. Szpakowski JL, et al. reported that HBV-related
mortality was four times more common in males than in
females [28] (Causes of death in patients with hepatitis
B: a natural history cohort study in the United States).
Our results showed that SS rate was not lower in male
than in female patients for non-HBV related liver failure,
but was lower in male than in female patients for HBV
related liver failure although having not reached a statis-
tically significant difference. However, the results of sub-
group analysis based on different age groups showed
that SS rates were all lower in male than in female pa-
tients with HBV related liver failure among each age
group from 25 to 54 years old, and reached a statistically
significant difference in cases of ages 40 to 44 years old.
Interestingly, SS rates of male patients were higher than
those of female patients in age <25 years (59.8 % versus
43.5 %) and ≥55 years (18.7 % versus 16.4 %) group,
though having no statistically significant difference.
These findings further indicated that male was also asso-
ciated with a poor prognosis of HBV related liver failure
in the middle-aged patients.
Conclusions
In conclusion, etiologies of liver failure were numerous
and varied during the 13 year period between 2000 and
2012 in southwest China. Recent years, there have been
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some new changes in clinical and epidemiological char-
acteristics of liver failure, in practical work, knowing
these are helpful to judge the diagnosis and prognosis of
liver failure, and then take positive and effective mea-
sures so as to reduce the mortality of liver failure. HBV
was the most leading cause of liver failure, and abso-
lutely predominated especially in the etiologies of ACLF.
AVT related hepatitis B flares increased progressively,
and had become the third leading cause of ACLF in
place of hepatotropic viruses superinfection and drugs.
The prognosis of liver failure remained very poor, but
had markedly improved in recently 3 years. ACLF pa-
tients induced by alcohol, drugs, NUCs withdrawal and
HBV resistance had worse prognosis than those induced
by spontaneous SAE of CHB. Liver failure induced by
reactivation of HBV or HCV due to steroids use was not
uncommon, and had an extremely high mortality. Male
was at higher risk for liver failure and death compared
to female in the middle-aged HBsAg carriers. Older age
was associated with a poor prognosis of liver failure, es-
pecially in male patients with HBV related liver failure.
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